Our Pricing

Wegovy UK: Complete Guide to Accessing Semaglutide Weight Loss Treatment

Wegovy UK availability has transformed weight management options for patients seeking clinically proven semaglutide treatment through registered pharmacies. As a UK-licensed GPhC-registered pharmacy, Cured Pharmacy provides transparent access to Wegovy from £69.00, with all prescriptions issued following clinical assessment by our UK-registered prescribers. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every patient receives genuine MHRA-approved medication with comprehensive support throughout their weight loss journey.

What Is Wegovy UK and How Does It Work for Weight Loss?

Wegovy UK is the brand name for semaglutide 2.4mg, a once-weekly injectable medication licensed by the MHRA specifically for chronic weight management in adults with obesity or overweight conditions [1]. The active ingredient semaglutide belongs to a class of medicines called GLP-1 receptor agonists, which work by mimicking a naturally occurring hormone that regulates appetite and food intake. Clinical trials have demonstrated that Wegovy helps patients feel fuller for longer, reduces hunger signals, and slows gastric emptying, creating the physiological conditions that support sustainable weight reduction [2].

In the landmark STEP clinical trial programme, patients using Wegovy UK achieved an average weight loss of 15% of their initial body weight over 68 weeks when combined with lifestyle modifications [2]. This represents significantly greater weight reduction compared to lifestyle changes alone, positioning Wegovy as one of the most effective pharmacological interventions currently available for obesity management. The medication requires a prescription following clinical assessment, as our UK-registered prescribers must evaluate your medical history, current medications, and suitability criteria before approving treatment.

At Cured Pharmacy, we supply genuine Wegovy UK manufactured by Novo Nordisk, ensuring you receive the same quality medication available through NHS prescriptions and high-street pharmacies. Every pen device is stored in temperature-controlled facilities and dispatched with cold-chain packaging to maintain medication integrity throughout delivery.

Wegovy UK Pricing: Transparent Costs with No Hidden Fees

Understanding the true cost of Wegovy UK treatment requires transparency about what you're actually paying for. At Cured Pharmacy, Wegovy is priced from £69.00 per pen, with the exact cost depending on your prescribed dosage strength. This price includes the medication, clinical consultation with a UK prescriber, prescription issuance, and dispensing by our registered pharmacists. Unlike some providers, we display prices before you complete any consultation, ensuring you can make informed decisions about your treatment costs.

The Wegovy UK dosage escalation schedule typically begins at 0.25mg weekly, gradually increasing over 16-20 weeks to the maintenance dose of 2.4mg weekly [1]. This titration approach minimises gastrointestinal side effects whilst allowing your body to adjust to the medication. New patients can Save £20 off their first order using code Weightlossnew, reducing the initial financial commitment whilst you assess treatment tolerability and effectiveness.

Our pricing structure reflects our commitment to making Wegovy UK accessible without compromising on clinical safety or medication quality. Every prescription undergoes review by superintendent pharmacist Tarun Kumar, ensuring appropriate dosing, interaction screening, and patient suitability before dispensing.

What's Included in Your Wegovy UK Treatment Package

Your Wegovy UK order from Cured Pharmacy includes comprehensive clinical support beyond just the medication itself. The package encompasses a free online consultation completed in under three minutes, clinical assessment by a UK-registered prescriber, prescription issuance if deemed appropriate, pharmacist dispensing and safety checks, discreet packaging with no external pharmacy branding, and next-day delivery options for urgent treatment needs. We also provide patient information leaflets, injection technique guidance, and access to our clinical team for any questions during your treatment course.

How to Buy Wegovy UK Online Through Cured Pharmacy

Purchasing Wegovy UK through our online pharmacy follows a straightforward clinical pathway designed to meet MHRA and GPhC regulatory requirements. The process begins with completing our online medical questionnaire, which collects essential information about your weight, height, medical history, current medications, and previous weight loss attempts. This consultation typically takes under three minutes and asks the same questions a GP would during an in-person appointment for weight management medication.

Once submitted, your Wegovy UK consultation reaches one of our UK-registered prescribers for clinical review. They assess your BMI, evaluate contraindications, screen for drug interactions, and determine whether semaglutide treatment aligns with NICE guidelines for weight management prescribing [3]. If approved, your prescription is electronically transmitted to our dispensary where registered pharmacists prepare your medication for dispatch. Patients typically receive their Wegovy UK order within 24-48 hours via tracked courier, with discreet packaging that protects your privacy.

For patients requiring ongoing Wegovy UK treatment, we offer subscription services that automatically process repeat prescriptions at your chosen interval. This ensures continuity of treatment without gaps that could compromise your weight loss progress or require restarting the dose escalation schedule.

Wegovy UK Prescription Requirements and Eligibility Criteria

To receive a Wegovy UK prescription, patients must meet specific clinical criteria established by NICE and the MHRA. Generally, you need a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [3]. Our prescribers also consider your previous weight loss attempts, current lifestyle modification efforts, and commitment to dietary and exercise changes alongside medication. Wegovy UK is not suitable for patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease.

Wegovy UK Dosing Schedule and Administration Guidance

The Wegovy UK dosing protocol follows a carefully designed escalation schedule that balances efficacy with tolerability. Treatment begins at 0.25mg injected subcutaneously once weekly for four weeks, then increases to 0.5mg weekly for four weeks, followed by 1mg weekly for four weeks, then 1.7mg weekly for four weeks, before reaching the maintenance dose of 2.4mg weekly [1]. This gradual titration allows your gastrointestinal system to adapt to semaglutide's effects, significantly reducing the likelihood of nausea, vomiting, and diarrhoea that can occur with rapid dose increases.

Each Wegovy UK pen is pre-filled and designed for single-dose administration, eliminating the need for manual dose measurement or vial preparation. Patients inject the medication into the abdomen, thigh, or upper arm, rotating injection sites weekly to prevent lipodystrophy. The injection itself takes seconds and uses a fine needle that most patients find comfortable. Our pharmacists provide detailed injection technique videos and written instructions with every order, ensuring you feel confident administering your Wegovy UK treatment at home.

Consistency in injection timing optimises Wegovy UK effectiveness, though the specific day of the week can be chosen based on your schedule. If you miss a dose and it's been less than five days, inject as soon as you remember; if more than five days have passed, skip that dose and resume your regular schedule [1]. Never double-dose to compensate for missed injections.

Wegovy UK Side Effects and How to Manage Them

Like all GLP-1 receptor agonists, Wegovy UK can cause side effects, with gastrointestinal symptoms being most common during the initial dose escalation phases. Clinical trial data shows that nausea affects approximately 44% of patients, diarrhoea 30%, vomiting 24%, and constipation 24%, though these rates decrease significantly as treatment continues and the body adapts to semaglutide [2]. Most gastrointestinal side effects are mild to moderate in severity and resolve within days to weeks without requiring treatment discontinuation.

To minimise Wegovy UK side effects, our clinical team recommends several evidence-based strategies. Eating smaller, more frequent meals rather than large portions reduces gastric distension and nausea. Avoiding high-fat, greasy, or spicy foods during the first few weeks of each dose increase decreases the likelihood of digestive discomfort. Staying well-hydrated helps prevent constipation, whilst ginger tea or other natural remedies may alleviate nausea for some patients. If side effects become severe or persistent, our prescribers can adjust your Wegovy UK dosing schedule, temporarily maintaining a lower dose before attempting further increases.

Serious but rare side effects require immediate medical attention and include signs of pancreatitis (severe abdominal pain radiating to the back), gallbladder problems (yellowing of skin or eyes, severe upper abdominal pain), or allergic reactions (facial swelling, difficulty breathing, severe rash). Our clinical team remains available throughout your Wegovy UK treatment to address concerns and provide guidance on symptom management.

When to Contact Your Prescriber About Wegovy UK Side Effects

Whilst mild gastrointestinal symptoms are expected with Wegovy UK, certain situations warrant clinical review. Contact our prescribers if you experience persistent vomiting that prevents adequate fluid intake, severe abdominal pain that doesn't resolve with standard measures, signs of dehydration such as dark urine or dizziness, unexplained visual changes, or symptoms of low blood sugar if you're taking other diabetes medications alongside Wegovy UK. Our team can assess whether dose adjustment, temporary treatment pause, or alternative weight management approaches would be more appropriate for your individual circumstances.

Wegovy UK Results: What Weight Loss Can You Expect?

Clinical evidence from the STEP trials provides robust data on expected Wegovy UK outcomes when used as part of a comprehensive weight management programme. In the STEP 1 trial involving 1,961 adults with obesity, participants using Wegovy 2.4mg achieved a mean weight loss of 14.9% from baseline over 68 weeks, compared to 2.4% with placebo [2]. Approximately 83.5% of Wegovy UK patients lost at least 5% of their body weight, 66.1% lost at least 10%, and 50.5% achieved 15% or greater weight reduction [2].

Individual Wegovy UK results vary based on numerous factors including starting BMI, adherence to lifestyle modifications, genetic factors affecting metabolism, and consistency with weekly injections. Patients who combine semaglutide treatment with structured dietary programmes and regular physical activity typically achieve superior outcomes compared to those relying on medication alone. Weight loss generally begins within the first four weeks of Wegovy UK treatment and continues progressively throughout the dose escalation period, with most patients reaching their maximum weight reduction between months 6-12 of continuous therapy.

Long-term weight maintenance with Wegovy UK requires ongoing treatment, as clinical trials demonstrate weight regain when semaglutide is discontinued [2]. Our prescribers work with patients to develop sustainable lifestyle habits that support weight management both during and potentially after Wegovy UK treatment, though many patients choose to continue medication long-term given its chronic disease management indication.

Factors That Influence Your Wegovy UK Weight Loss Success

Maximising Wegovy UK effectiveness requires attention to several modifiable factors within your control. Adherence to the prescribed dosing schedule ensures consistent GLP-1 receptor activation and appetite regulation. Implementing a moderate calorie deficit through portion control and nutritious food choices amplifies the medication's metabolic effects. Regular physical activity, even moderate-intensity walking for 150 minutes weekly, enhances fat loss whilst preserving lean muscle mass during weight reduction. Adequate sleep of 7-9 hours nightly optimises hormones that regulate hunger and metabolism. Our clinical team can provide personalised guidance on optimising these factors to support your Wegovy UK treatment outcomes.

Scientific References

1. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 15 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. [accessed 15 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.